Search results for "enolate"
showing 10 items of 52 documents
CCDC 2060887: Experimental Crystal Structure Determination
2021
Related Article: Lucija Ptiček, Lucija Hok, Petra Grbčić, Filip Topić, Mario Cetina, Kari Rissanen, Sandra Kraljević Pavelić, Robert Vianello, Livio Racané|2021|Org.Biomol.Chem.|19|2784|doi:10.1039/D1OB00235J
CCDC 831305: Experimental Crystal Structure Determination
2012
Related Article: M.Giese, M.Albrecht, G.Ivanova, A.Valkonen, K.Rissanen|2012|Supramol.Chem.|24|48|doi:10.1080/10610278.2011.622384
Physiological and metabolic actions of mycophenolate mofetil on cultured newborn rat cardiomyocytes in normoxia and in simulated ischemia
2004
Mycophenolate mofetil (MMF) is a new immunosuppressive drug used to reduce acute rejection after heart transplantation. As with other immunosuppressive drugs, MMF therapy is associated with several adverse effects. However, the direct effects of MMF on myocardial tissue has not been yet evaluated. The aim of the work was thus to evaluate the effects of MMF on isolated cardiomyocytes (CM) in normal conditions and in an in vitro model of simulated ischemia (SI; substrate-free hypoxia) and reperfusion (R; reoxygenation). Myocyte-enriched cultures were prepared from newborn rat heart ventricles. The transmembrane potentials were recorded using conventional microelectrodes and the cell contracti…
Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus.
2010
BACKGROUND: One of the major goals of pemphigus therapy is to reduce the patient's cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. OBSERVATIONS: Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
2017
Abstract Background Few studies investigated the role of mycophenolate mofetil in inflammatory bowel disease, and none of them had specifically focused on patients with previous multiple intolerances and/or nonresponses to conventional immunosuppressants and biologics. Aims To evaluate clinical benefit and tolerability profile of mycophenolate mofetil in patients with inflammatory bowel disease and limited treatment options. Methods All consecutive patients with previous multiple intolerances and/or nonresponses to immunosuppressants and biologics who started an off-label treatment with mycophenolate mofetil from January 2014 to February 2016 were entered in a prospectively maintained datab…
Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.
2000
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…
Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant
2009
We assessed the efficacy and outcome of low through level of calcineurin inhibitors (CNI) and introducing mycophenolate mofetil (MMF) in liver transplant (LT) patients with CNI-related renal dysfunction. Thirty LT patients were converted to combined therapy and compared with 30 patients used as a contemporary control group receiving CNI only. The two groups were matched for sex, age, months after LT, immunosuppressive treatment, creatinine level, presence of diabetes and calculated glomerular filtration rate (GFR) via Cockroft-Gault method. After two years, in the MMF serum creatinine decreased from 1.65 mg/dL (range 1.33-3.5) to 1.4 mg/dL (range 0.9-4.7) (p = 0.002) and GFR increased from …
Mycophenolate mofetil for treatment of active inflammatory bowel disease. Clinical and immunological studies.
1998
Tetrazola hemiamināls kā hirāla palīggrupa
2017
Tetrazola hemiamināls kā hirāla palīggrupa. Sējējs M., zinātniskais vadītājs Prof., Dr. chem. Sūna E., konsultēja MSc. chem., Kinēns A. Maģistra darbs uzrakstīts latviešu valodā, tā apjoms 58 lapaspuses. Darbs satur 56 attēlus, 5 tabulas. Maģistra darbs veltīts terazolu hemiaminālu hirālās palīggrupas iegūšanai un pielietojumam diastereoselektīvajā sintēzē. Izstrādātās hirālās palīggrupas efektivitāte demonstrēta, ar augstu diastereoselektivitāti veicot karbonskābju α-pozīcijas fluorēšanas un nitrozo-aldola reakcijas. Darba rezultātā izstrādāts tetrazola hemiamināla hirālās palīggrupas stereoindukcijas modelis. Demonstrēta hirālās palīggrupas šķelšana maigos reakcijas apstākļos. Tetrazola h…